(P 062) WHAT IS THE CLINICAL IMPACT OF STAGING AND SURVEILLANCE PET-CT SCAN FINDINGS IN PATIENTS WITH BONE AND SOFT TISSUE SARCOMA?

Author(s)

Linus Lee, BE

Clinical Research Fellow
Rush University Medical Center
Chicago, Illinois, United States

Co-Author(s)

Gayathri Vijayakumar, BS

Research Fellow
Rush University Medical Center
Chicago, Illinois, United States
AK

Alexander Kazmer, N/A, BS

Rush University Medical Center
Chicago, Illinois, United States
MC

Matthew W. Colman, MD

Rush University Medical Center
Chcago, Illinois, United States
SG

Steven Gitelis, MD

Rush University Medical Center
Chicago, Illinois, United States
MB

Marta Batus, MD

Rush University Medical Center
Chicago, Illinois, United States
Alan T. Blank, MD, MS

Assistant Prof
Rush University Medical Center
chicago, Illinois, United States

Objective: PET-CTs are becoming increasingly utilized in sarcoma care, workup, and surveillance. This study aimed to describe additional PET-CT findings as well as subsequent workups and changes in clinical course due to those results.

Methods: Patient records were retrospectively reviewed, and the additional workups and evaluations triggered by PET-CT findings were qualitatively analyzed to document their results. Additional changes in clinical course were documented.

Results: A total of 183 bone and soft tissue sarcoma patients underwent PET-CT as part of staging or surveillance. Additional workup was performed in 31.5% (n=41 of 130) patients who had positive PET-CT findings. Among these, 36.6% (n=15 of 41) patients had clinically significant findings that altered the clinical course. Overall, 14.8% (n=27 of 183) experienced a change in clinical course due to PET-CT.

Conclusion: PET-CT often highlights lesions of potential clinical importance. Additional workup as well as change in clinical course were not infrequent. Future, multi-institutional studies should address the value of PET-CT in sarcoma care.